Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.

Abstract: The present invention relates to a method for producing of a cell and/or tissue and/or disease phase specific medicament against against chronic inflammatory diseases. Disease, cell type, tissue and/or stage specific proteins and nucleic acids are identified with regard to their modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and autoimmune diseases is provided.

Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.

Abstract: The invention relates to a method for the production of a cell and/or tissue and/or disease phase specific medicament against chronic inflammatory diseases. Disease, cell-type, tissue and/or stage specific proteins and nucleic acids are identified with regard to the modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and auto-immune diseases is provided.